Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LR20061
- Development stage
- Preclinical
- Lead developer
- LG Chem
01
Overview
LR20061 is a research-stage therapeutic candidate being developed by LG Chem for the treatment of atopic dermatitis. Currently in the discovery or preclinical phase, the program's specific molecular target and modality have not been publicly disclosed by the sponsor. It is part of LG Chem's immunology pipeline, which focuses on developing novel treatments for chronic inflammatory skin conditions. As a research-stage asset, it represents an early-stage exploration into the pathophysiology of atopic dermatitis, aiming to address unmet needs in the management of this prevalent dermatological disease.
Beyond the preview
Go deeper on LR20061.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LR20061.